DIA

7 September
8.45am – 5pm (SGT)
Virtual Meeting

2021 **ASIA** MEETING

THE EVOLUTION OF CLINICAL TRIALS AND REGULATORY SCIENCE IN A POST-PANDEMIC DIGITAL WORLD IN ASIA

The COVID-19 outbreak brought unprecedented changes to the way we live and work, especially in the R&D field. DIA Asia 2021 will be the first transnational post-COVID conference connecting industry experts and regulators to discuss key learnings and takeaways in the clinical trial and regulatory space across the Asia region. Current learnings will create a post-pandemic view on the new regulatory landscape, innovative virtual trials, Real-World Evidence and the potential implications to accelerate drug development.

Join this multi-stakeholder, neutral forum to:

- Explore new technology adoptions in revolutionizing healthcare for better diagnostics and patient outcomes.
- Receive updates on regulatory processes, policies, innovative drug review pathways, software regulations and adoption of virtual inspections.
- Learn how clinical trials are taking a more patient centric approach and get updated on the implementation of remote monitoring in Asia and the challenges that arise.
- Understand the regulations surrounding nutraceuticals/nutrition and their role in today's healthcare.

Why you should attend:

- This is the very first time that DIA is hosting a transnational conference in the Asia region.
- The meeting provides a unique forum to gain a holistic view on the clinical trial and regulatory space post-COVID evolution.
- Join this virtual meeting from all over the world to learn about the latest developments in the Asia region.

This meeting is the ideal place for:

- Industry professionals in Pharmaceuticals and Medical Technologies involved in Research & Development, Regulatory Affairs, and Medical Affairs.
- Regulators and personnel from Health Authorities and Ministries.
- Patient and Patient Support Groups.
- Experts from Academia and Research.

PROGRAM Chair

Jin Shun | Head, Regulatory Competency Center Asia Pacific, Middle East and Africa (APMA), Sandoz

Program Committee Members

Jing Ping Yeo | Director, Research Integrity, Compliance and Ethics, Singapore Health Services

Kum Cheun Wong | Head Asia Pacific Regulatory & Development Policy, Novartis Asia Pacific Pharmaceuticals Pte Ltd

Vicky Han | Senior Director - Policy Group Lead for Asia Pacific, Global Regulatory Affairs, Janssen Pharmaceuticals

Jessica Liu | VP, Head of International Business, Tigermed Co. Ltd. Former CEO, DreamCIS, Korea., One Tigermed Company

Ling Su | Venture Partner, LAV (Lilly Asia Ventures)

Rie Matsui | Senior Director, Regional Labeling Head for APAC, International Labeling Group (ILG), Global Regulatory Affairs, Pfizer R & D Japan

Junko Sato | Director, Office of International Programs, Pharmaceuticals and Medical Devices Agency (PMDA)

Hideki Maeda | Professor, Department of Regulatory Science, Meiji Pharmaceutical University

Shinichi Nishiuma | Head of Oncology Medical Science, Japan medical, Bristol Myers Squibb K.K

SPEAKER HIGHLIGHTS

JOIN US

Danny Soon

Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore, Executive Director, Singapore Clinical Research Institute

Takahiro Nonaka

Head of Epidemiology, Medical information Division, PMDA

K. Arnold Chan

Professor and Director, NTU Health Data Research Center Taipei, TAIWAN

PROGRAM

8.45 – 9:00 AM

Welcome and Opening Remarks

Jin Shun | Head - Regulatory Competency Center Asia Pacific, Middle East and Africa (APMA), Sandoz

9.00 – 9.45 AM

Opening Plenary: Bio-Venture / Mega-Pharma Building Ecosystems in Asia

Session Chair (s)

Junko Sato | Director - Office of International Programs, Pharmaceuticals and Medical Devices Agency (PMDA)

Jing Ping Yeo | Director - Research Integrity, Compliance and Ethics, Singapore Health Services

9.00 – 9.15 AM

Bio-Venture / Mega-Pharma Building Ecosystems in Asia

Danny Soon | Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore, Executive Director, Singapore Clinical Research Institute

9.15 – 9.45 AM

Panel Discussion

Panelists (To be announced)

9.45 – 10.45 AM

Session 1 : MRCT During COVID and Post COVID

Session Chair (s)

Jing Ping Yeo | Director - Research Integrity, Compliance and Ethics, Singapore Health Services

Jessica Liu | VP, Head of International Business, Tigermed Co. Ltd. , Former CEO, DreamCIS, Korea., One Tigermed Company

9.45 – 10.05 AM

How Regulators can Accelerate the MRCT Application Process

Speaker Invited

10.05 – 10.25 AM

Paradigm of Complex Innovative Clinical Trial Design (platform trial, basket trial design, or master protocol etc.) during and Post COVID-19

James Pan | J&J R&D

10.25 – 10.45 AM

Industry Practice Using Virtual Clinical Trials (how collaborations can help streamline research conduct)

Jing Liu | Vice President and Head of Medical Services APAC Parexel

10.45 – 11.00 AM

Q&A

11.00 – 11.15 AM

Tea / Coffee Break

11.15 – 12.45 PM

Session 2: RWE

Session Chair (s)

Kum Cheun Wong | Head Asia Pacific Regulatory & Development Policy, Novartis Asia Pacific, Pharmaceuticals Pte Ltd

Shinichi Nishiuma | Head of Oncology Medical Science, Japan Medical, Bristol Myers Squibb K.K

11.15 – 11.40 AM

RWE for Regulatory Decision-JP Perspective (focus on disease registry)

Takahiro Nonaka | Head of Epidemiology, Medical Information Division, PMDA

11.40 – 12 .05 AM

Perspective from Academia

K. Arnold Chan | Professor and Director, NTU Health Data Research Center, Taipei, TAIWAN

12.05 – 12.30 PM

Perspective from Industry

Gorana Capkun | Global Head RWE, Novartis Oncology

12.30 – 12.45 PM

Q&A

12.45 – 1.30 PM

Lunch Break

1.30 – 3.00 PM

Session 3: Digital Technology Advances Regulatory Modernisation & Drug Development

Session Chair (s)

Vicky Han | Senior Director - Policy Group Lead for Asia Pacific, Global Regulatory Affairs Janssen Pharmaceuticals

Rie Matsui | Senior Director, Regional Labeling Head for APAC, International Labeling Group (ILG), Global Regulatory Affairs, Pfizer R & D Japan

1.30 – 1.50 PM

De-centralised Clinical Trial in China: Progress and Practice

Tong GOU | Executive Vice President, LinkDoc Technology Co. Ltd.

1.50 – 2.10 PM

Formal Implementation of E-Labelling in Japan

Tomoko Osawa | Office Director, Office of informatics and Management for Safety, PMDA

2.10 – 2.30 PM

Digital Endpoint Ecosystem & Protocols

Kai Langel | Director, Janssen Clinical Innovation Janssen R&D

2.30 – 3.00 PM

Panel Discussion: Digital Transformation in Regulatory Affairs

Panellists

Tomoko Osawa | Office Director, Office of informatics and Management for Safety, PMDA

Kai Langel | Director, Janssen Clinical Innovation Janssen R&D

Shimon Yoshida | Executive Director Head of International Labeling Group, Global Regulatory Affairs, Global Product Development, Pfizer R&D UK

Tong GOU | Executive Vice President, LinkDoc Technology Co. Ltd.

3.00 – 4.00 PM

Innovation Hub

4.00– 5.00 PM

Networking

REGISTRATION FEES

Early Bird
(Until 7 August 2021, subject to payment confirmation)

Group Discount
A group of 5 - 15%/PAX
A group of 7 and more - 20%/PAX

Attendee Fee	Early Bird		Standard Rate	
	Member	Non-Member	Member	Non-Member
Industry	USD 227	USD 302	USD 302	USD 380
Academia/Charitable	USD 151	USD 190	USD 228	USD 265
Government / Regulators	USD 151	USD 190	USD 228	USD 265
Student		SGD 100		

PAYMENT DETAILS:

DIA INDIA PRIVATE LIMITED
Office #250, Unit#1, Level 2, B Wing,
Times Square, Andheri Kurla Road,
Andheri (E),
Mumbai- 400059.
tel: +91-22-6608 9588
email: India@diaglobal.org

Wire Transfer Instructions for DIA India Private Limited: Axis Bank Ltd
Dhiraj Baug, Near Hari Niwas Circle
LBS Marg, Thane West-400 602
ACCOUNT #061010200024611
IFSC CODE: UTIB0000061
SWIFT CODE: AXISINBB061
BSR CODE: 6360061

CANCELLATION POLICY:

On or before august 7, 2021

- Cancellations must be in writing and received by August 7, 2021. Registrants who do not cancel in writing by that date and do not attend
  the event will be responsible for the full registration fee paid. Registrants
  are responsible for cancelling their own hotel and airline reservations.
- DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.
- UPON CANCELLATION, the administrative fee that will be withheld from refund amount is 25 % of the delegate fee

Full meeting cancellation

- All refunds will be issued in the currency of the original payment

SPONSORSHIP:

If you want to get access to the top experts in the field, exhibition and sponsoring activities might be your way.
Please contact us for further information

Kanchan Patel | Kanchan.Patel@DIAglobal.org
Shamiq Hussain | Shamiq.hussain@diaglobal.org

REGISTER:

Please visit our website for more information and to register online or contact us for group discounts: Kanchan.Patel@DIAglobal.org